^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    obrixtamig (BI 764532)

    i
    Other names: BI 764532, OBT620, BI-764532, OBT-620, BI764532, OBT 620
    Company:
    Boehringer Ingelheim, Oxford BioTherapeutics
    Drug class:
    CD3 agonist, DLL3 inhibitor
    Related drugs:
    2d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    8d
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Sep 2026 --> Apr 2027
    Trial completion date
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    19d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Not yet recruiting, Boehringer Ingelheim | Trial completion date: Apr 2029 --> Jul 2029
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    1m
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Not yet recruiting, Boehringer Ingelheim
    New P3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    2ms
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    2ms
    DAREONTM-9: DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Jul 2027
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    topotecan • obrixtamig (BI 764532)
    2ms
    Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy. (PubMed, Med Oncol)
    This study systematically characterized three clinical-stage CD3×DLL3 BsAbs, Tarlatamab (AMG757), BI764532 and HPN328, via structural modeling, T-cell activation assays, cytokine profiling, and tumor cytotoxicity tests. BI764532 demonstrated a balanceed efficacy (ORR 18% in SCLC), while Tarlatamab achieved an ORR range of 13-40% across clinical trials. IS distance and epitope binding are strongly correlated with efficacy and safety of DLL3-targeted BsAbs, providing a critical framework for optimizing T-cell engager design in cancer immunotherapy.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    obrixtamig (BI 764532) • Imdelltra (tarlatamab-dlle) • gocatamig (MK-6070)
    3ms
    DAREON-5: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers (clinicaltrials.gov)
    P2, N=174, Recruiting, Boehringer Ingelheim | Trial completion date: Jul 2027 --> Feb 2028 | Trial primary completion date: Jan 2027 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    obrixtamig (BI 764532)
    4ms
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial primary completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)
    5ms
    DareonTM: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers (clinicaltrials.gov)
    P2, N=174, Recruiting, Boehringer Ingelheim | Trial primary completion date: Oct 2026 --> Jan 2027
    Trial primary completion date
    |
    obrixtamig (BI 764532)
    5ms
    DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers (clinicaltrials.gov)
    P1, N=55, Recruiting, Boehringer Ingelheim | Trial completion date: Aug 2026 --> Apr 2027 | Trial primary completion date: Jul 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • etoposide IV • obrixtamig (BI 764532)
    5ms
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)